Research and Markets: Small Intestine Cancer - Pipeline Review, H1 2012
March 15 2012 - 10:51AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/925269/small_intestine_ca)
has announced the addition of Global Markets Direct's new report
"Small Intestine Cancer - Pipeline Review, H1 2012" to their
offering.
Global Markets Direct's, 'Small Intestine Cancer - Pipeline
Review, H1 2012', provides an overview of the Small Intestine
Cancer therapeutic pipeline. This report provides information on
the therapeutic development for Small Intestine Cancer, complete
with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the
therapeutic development for Small Intestine Cancer. 'Small
Intestine Cancer - Pipeline Review, H1 2012' is built using data
and information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources, put together by
Global Markets Direct's team.
Scope
- A snapshot of the global therapeutic scenario for Small
Intestine Cancer.
- A review of the Small Intestine Cancer products under
development by companies and universities/research institutes based
on information derived from company and industry-specific
sources.
- Coverage of products based on various stages of development
ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Small Intestine Cancer pipeline on the basis of
route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of
therapeutics under development for Small Intestine Cancer.
- Identify emerging players with potentially strong product
portfolio and design effective counter-strategies to gain
competitive advantage.
- Plan mergers and acquisitions effectively by identifying
players with the most promising pipeline.
- Devise corrective measures for pipeline projects by
understanding Small Intestine Cancer pipeline depth and focus of
Small Intestine Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline.
For more information visit
http://www.researchandmarkets.com/research/925269/small_intestine_ca.